Biotech Stock News: Bristol-Myers Partner Celgene for Oncology Treatments

biotech_industry_08-512x384

In a move which can have a lasting impact in the biotech segment of the stocks market, Bristol-Myers Squibb Company (BMY) entered into a collaboration with Celgene Corporation (CELG) to asses the safety, tolerability and preliminary efficacy of a cocktail therapy including its high potential immuno-oncology drug Opdivo (nivolumab, a PD-1 immune checkpoint inhibitor) and Celgene’s oncology treatment Abraxane in a phase I study.

The study, which will commence in the final quarter of the year, will evaluate multiple cancer forms. Celgene will be responsible for conducting the study.

Bristol-Myers stated in its press release that while patients suffering from HER-2 negative breast cancer will be treated with a combination of Abraxane and Opdivo, Eli Lilly’ and Company’s (LLY) Gemzar will also be added to the above combination in patients with pancreatic adenocarcinoma. Meanwhile, patients suffering from non-small cell lung cancer will be treated with a combination of Opdivo, Abraxane and chemotherapy drug carboplatin.

Biotech Stock News

Financial details pertaining to the pact were not revealed. We expect investor focus to remain on this oncology deal involving two major players in the biopharmaceutical space. We note that Opdivo holds immense potential in the lucrative as well as highly sought after immuno-oncology space. The treatment was approved in Japan in July this year for treating patients with unresectable melanoma.

Following the Japanese approval, Opdivo became the first PD-1 immune checkpoint inhibitor to gain approval. Ono Pharmaceutical has the rights to commercialize the treatment in Japan, as per a 2011 agreement with Bristol-Myers. Bristol-Myers intends to seek U.S. approval for its immuno-oncology drug by Sep 30, 2014.

Biotech News Video

Watch this video for more “Biotech” news.

[grabpress_video guid=62c4a5774f3266964d11a28ba963bd81ebc72453 embed_id=2151917]

Biotech Financial News

Bristol-Myers is already seeking FDA approval for Opdivo in the third-line squamous cell non-small cell lung cancer indication. The company initiated a rolling submission to the FDA for a Biologics License Application for Opdivo. The rolling submission will allow Bristol-Myers to complete portions of the application which needs to be submitted and reviewed by the FDA on an ongoing basis. Bristol-Myers expects to complete the application by Dec 31, 2014.

Thanks for visiting the TechNews.org website. Be sure to catch all BioTech financial news, bookmark us and check all the videos and news articles regarding Biotech business news.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone